Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regeneration
University of California San Diego and  Ionis Pharmaceuticals Inc. (NASDAQ:IONS) researchers described in Cell Stem Cell an IRF4 antisense oligonucleotide (ASO), ION251, that reduced tumor growth, impaired myeloma progenitor regeneration and increased survival in xenograft mouse models of multiple myeloma (MM). ION251 is in a Phase I trial in relapsed MM patients.

Altering DNA methylation prevents myeloma bone diseaese
A team led by scientists from the Josep Carreras Leukaemia Research Institute and Bellvitge Biomedical Research Institute showed in Nature Communications that targeting DNA methyltransferases and EHMT2 with dual inhibitor CM-272 reduced tumor burden and prevented tumor-associated bone loss in a mouse model of myeloma...